Inter-Vendor Variability of Perfusion Parameters Derived from Dynamic Contrast-Enhanced MRI in Patients with Prostate Cancer
Open Access
- 23 June 2026
- journal article
- research article
- Published by MDPI AG in Tomography
- Vol. 12 (7) , 91
Abstract
Purpose: To investigate the agreement on perfusion parameters derived from two different commercially available solutions for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients with prostate cancer (PCa). Methods: A total of 50 patients (mean age, 71.6; range 56–86) who had undergone radical prostatectomy between December 2021 and September 2022 were included in this retrospective study. All patients had undergone DCE-MRI on a single 3T-MR scanner. Tumor segmentation on MR images was performed by two radiologists in consensus after radiologic-pathologic correlation using topographic maps as a reference standard. Subsequently, four perfusion parameters were calculated by dedicated commercially available solutions from two different vendors. Both solutions adopted a population-based arterial input function and an extended Tofts model as the pharmacokinetic model. The perfusion parameters were as follows; volume transfer constant (Ktrans), rate constant (kep), volume fraction of extravascular extracellular space (ve), and volume fraction of plasma (vp). The differences between paired measurements were compared by Bland–Altman analyses and the reproducibility was evaluated using the intraclass correlation coefficient (ICC). Results: The study population consisted of Gleason score (GS) 6 (n = 12), GS 7 (n = 34), GS 8 (n = 1), and GS 9 (n = 3). Significant differences were found for all parameters (p < 0.0001). Mean differences were as follows: Ktrans, −0.2102 (95% confidence interval; −0.2687 to −0.1518); kep, −0.7632 (−0.9005 to −0.6258); ve, −0.1507 (−0.2422 to −0.05907); vp, −0.02929 (−0.03383 to −0.02476). ICCs for average measures were as follows: Ktrans, 0.2989 (−0.2355 to 0.6021); kep, 0.6883 (0.4507 to 0.8231); ve, −0.1331 (−0.9967 to 0.3570); vp, 0.2653 (−0.3106 to 0.5881). Conclusion: All perfusion parameters were significantly different between the two solutions. Therefore, comparison of perfusion parameters across different solutions is not recommended.Keywords
Funding Information
- Guerbet Research Grant (IIS-L.0164)
This publication has 15 references indexed in Scilit:
- Dynamic contrast-enhanced magnetic resonance imaging for risk stratification in patients with prostate cancerQuantitative Imaging in Medicine and Surgery, 2022
- The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis ChallengeTomography, 2016
- Perfusion and vascular permeability: Basic concepts and measurement in DCE-CT and DCE-MRIDiagnostic and Interventional Imaging, 2013
- Angiogenesis in prostate cancer: onset, progression and imagingBJU International, 2012
- Overview of Dynamic Contrast-Enhanced MRI in Prostate Cancer Diagnosis and ManagementAmerican Journal of Roentgenology, 2012
- Dynamic contrast enhanced MRI in prostate cancerEuropean Journal of Radiology, 2007
- The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic CarcinomaAmerican Journal of Surgical Pathology, 2005
- The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendationsBritish Journal of Cancer, 2005
- Discrimination of Prostate Cancer from Normal Peripheral Zone and Central Gland Tissue by Using Dynamic Contrast-enhanced MR ImagingRadiology, 2003
- Predictors of pathologic stage in prostatic carcinoma. The role of neovascularityCancer, 1994